Episode 251: PREMIUM – a new heart failure study and much, much more
In episode 251, PREMIUM Mike and James look at the most recent update of the ACCORD trial and find not a lot. We then look at a relatively new class of medication (neprilysin inhibitor) and actually find something but realise it all needs to be put into context.
1) Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.
2) PARADIGM-HF – Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure